Ken Griffin Achilles Therapeutics PLC Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Achilles Therapeutics PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 104,993 shares of ACHL stock, worth $99,743. This represents 0.0% of its overall portfolio holdings.
Number of Shares
104,993
Previous 108,454
3.19%
Holding current value
$99,743
Previous $96,000
36.46%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding ACHL
# of Institutions
34Shares Held
23.5MCall Options Held
0Put Options Held
0-
Syncona Portfolio LTD Guernsey, Channel Islands, X011.1MShares$10.5 Million9.24% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.39MShares$2.27 Million0.42% of portfolio
-
Redmile Group, LLC San Francisco, CA1.61MShares$1.53 Million0.08% of portfolio
-
Vestal Point Capital, LP New York, NY1.5MShares$1.43 Million0.16% of portfolio
-
Ikarian Capital, LLC Dallas, TX1.44MShares$1.37 Million0.24% of portfolio
About Achilles Therapeutics plc
- Ticker ACHL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,774,000
- Market Cap $38.7M
- Description
- Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...